【Probe 24H】New study finds that AIDS is expected to be cured! The proportion of adverse drug reactions in the elderly population continues to rise

New study finds that AIDS is promising; The proportion of adverse drug reactions in the elderly population continued to rise; Ferring Pharma Publishes Seven Analysis Reports for RBX2660.
.
.
BioDiscovery will pay attention to the "medicine" smell with you and explore the value of biotechnology!

01 New study finds promise for a cure for AIDS

On October 17, a study from the University of Oshu in Denmark was published in Nature Medicine
.
The study found an experimental drug
that can improve the body's own ability to suppress HIV.

The researchers found that while existing ART (antiretroviral therapy) can suppress the amount of virus in the blood and gradually regulate the immune system, if a patient stops ART, the amount of virus in the patient's body returns to the pre-treatment level
after a brief suppression.

To address this, the researchers divided subjects with pre-existing HIV into four groups, adding a drug variable
to the premise that all people received ART.
After increasing the drug variables, the researchers found that if patients added HIV monoclonal antibody drugs at the beginning of ART therapy, the viral content in the patients not only decreased faster, but also developed some immunity to HIV, and even after they stopped using HIV monoclonal antibody drugs, the immune system was enhanced
.

This major discovery is undoubtedly a breakthrough, but the researchers also said that this discovery is still in the experimental stage, and in order to be applied as soon as possible, a lot of research and optimization are
still needed.

02 The proportion of adverse drug reactions in the elderly population continues to rise

On October 24, the State Food and Drug Administration replied to the Fifth Meeting of the 13th National Committee of the Chinese People's Political Consultative Conference No.
00079 "Proposal on Attaching Importance to the Safety of Medication for the Elderly and Improving the Level of Pharmaceutical Services", which mentioned that with the aging of China's population and the improvement of the health care system, the amount of medication used by the elderly population continues to increase, and the proportion of adverse reactions continues to rise, and it is necessary to continuously strengthen the monitoring, evaluation and analysis and application
of adverse drug reactions in the elderly population.

In recent years, the NMPA has continued to strengthen the monitoring
of adverse drug reactions in the elderly population.
According to the adverse drug reaction monitoring data in 2021, the adverse reaction reports of elderly patients over 65 years old accounted for 31.
2% of
the total population reports.

In its reply, the NMPA said that for the situation found in the monitoring involving the increased risk of drug use for the elderly, the NMPA timely organized technical forces to carry out assessment, and took measures to ensure the safety of
medication for the elderly in accordance with the law.

03 Ferring Pharma publishes seven analysis reports on RBX2660

On October 24, Ferring presented seven analyses of RBX2660, a microbiota-based live biotherapeutic study with the goal of reducing recurrent Clostridium difficile infections
after antibiotic treatment, at the 2022 Annual Scientific Meeting of the American College of Gastroenterology.

One 24-month subgroup analysis looked at the sustained clinical response
of participants who received up to two doses of RBX2660.
Two post-mortem analyses examined PUNCH? Quality of life data
related to physical, psychological, and social health for CD3 clinical programs.
The oral presentation of the special efficacy and safety analysis of Phase 3 data on the first recurrence and comorbidities won the American College of Gastroenterology Colon Distinguished Research Award
.

"Clostridium difficile infection is a significant public health burden that can lead to a vicious cycle of recurrence that affects a person's long-term health
.
" Elizabeth Garner, MD, chief scientific officer of Ferring, said
.

04 ZaiJi Pharma raised $14 million in Series C+ financing

On October 24, Guangzhou Zaiji Pharma Technology Co.
, Ltd.
completed a $14 million Series C+ financing to support its portfolio
of eight small molecule targeted and immunotherapy drug candidates.
Zaiji Pharma's lead product is a small molecule PD-L1 inhibitor that matches
the efficacy of duvalumab in a human PD-1 knock-in mouse model.
The company is using its oral, radiotherapy imaging and transdermal platforms to develop products
for hematological cancers, solid tumors, and autoimmune diseases.
This round of C+ round of funds was raised
by LAPAM Capital, Zhongxin Capital and Deyirun Sunshine Venture Capital.

05 FDA accepts Novaliq's new drug application for the treatment of dry eye

On October 24, Novaliq, a biopharmaceutical company focused on eye therapeutics, announced that the FDA had accepted CyclASol? New Drug Application (Cyclosporine Eye Drops), a first-of-its-kind anti-inflammatory product
for the treatment of signs and symptoms of dry eye.

CyclASol？ Rapid onset of therapeutic effect, improved clinical significance and excellent tolerability
of patients with this indication have been demonstrated in two pivotal studies.
A 12-month long-term study confirmed that the effect was maintained or even improved
for most signs and symptom endpoints.

Christian Roesky, CEO of Novaliq, said, "This is an exciting time for ophthalmologists and optometrists and their patients as we are one step
closer to better treating the serious ocular surface disease that affects millions of Americans.
"If approved, CyclASol? It will become an effective and comfortable anti-inflammatory treatment
for dry eye patients.